Clinical and immunological effects of mRNA vaccines in malignant diseases

@article{Heine2021ClinicalAI,
  title={Clinical and immunological effects of mRNA vaccines in malignant diseases},
  author={Annkristin Heine and Stefan A Juranek and Peter Brossart},
  journal={Molecular Cancer},
  year={2021},
  volume={20}
}
In vitro -transcribed messenger RNA-based therapeutics represent a relatively novel and highly efficient class of drugs. Several recently published studies emphasize the potential efficacy of mRNA vaccines in treating different types of malignant and infectious diseases where conventional vaccine strategies and platforms fail to elicit protective immune responses. mRNA vaccines have lately raised high interest as potent vaccines against SARS-CoV2. Direct application of mRNA or its… 
Messenger RNA Based Vaccines and Their immunological effect on diseases
TLDR
In this review mRNA vaccines in detail were examined, as well as future objectives and challenges in the prevention of infectious diseases.
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
TLDR
Nonviral nanodelivery systems of mRNA vaccines used for cancer gene therapy and immunotherapy and effectively delivering mRNA into cells and successfully activating the immune response are the keys to the clinical transformation of mRNA therapy.
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
TLDR
The mRNA-based vaccines in development against various infectious diseases offer several advantages ranging from rapid design, generation, manufacturing, and administration and have strong potential to be used against various diseases in the future.
An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation.
TLDR
A protein-based all-in-one TCV platform that intracellularly codelivers tumor antigen and inflammasome activator to DCs to induce long-lasting antitumor T cell responses is proposed.
mRNA based vaccines as an alternative to conventional vaccine approaches
TLDR
This review summarizes current mRNA vaccine development, safety concerns, advances in delivery systems, clinical trials, and various therapeutic applications of mRNA vaccines.
Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2
TLDR
This review critically presents and discusses the COVID-19 mRNA vaccine-induced immunity, and it summarizes the most common anaphylactic and autoimmune adverse effects that have been identified until now after massive vaccination campaigns.
Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
TLDR
TP53, IDH1, C3, and TCF12 are effective antigens for the development of anti-glioma mRNA vaccines, and the classification of the immune subtypes of glioma may play a crucial role in the predicting mRNA vaccine outcome.
Influenza Viruses: Innate Immunity and mRNA Vaccines
TLDR
The current understanding of the innate immune response that uses pattern recognition receptors to detect and respond to mRNA vaccination is provided.
The First Approved COVID-19 Vaccines: The Road to Cancer Vaccines
In the past decade, mRNA vaccines have been highly discussed as a promising therapy for cancer. With the pandemic of COVID-19, some researchers redirected their studies to the development of a new
...
...

References

SHOWING 1-10 OF 241 REFERENCES
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
TLDR
First clinical data obtained from two separate Phase I/IIa trials conducted in PCA (prostate cancer) and NSCLC (non‐small cell lung carcinoma) patients have shown that the two‐component mRNA vaccines are safe, well tolerated and highly immunogenic in humans.
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
TLDR
A two-component mRNA-based tumor vaccine that supports both: antigen expression and immune stimulation, mediated by Toll like receptor 7 (TLR7), and induce balanced adaptive immune responses providing humoral as well as T cell mediated immunity is presented.
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.
TLDR
In tumor-bearing mice intralymphatic RNA vaccination elicited protective and therapeutic antitumor immune responses, resulting in a remarkable survival benefit as compared with other treatment regimens.
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
TLDR
It is shown that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress.
Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation
TLDR
A combinatorial library of ionizable lipid-like materials is developed to identify mRNA delivery vehicles that facilitate mRNA delivery in vivo and provide potent and specific immune activation, and result in limited systemic cytokine expression and enhanced anti-tumor efficacy.
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
TLDR
It is demonstrated here that such treatment is feasible and safe (phase 1 criteria) and an increase in antitumor humoral immune response was seen in some patients, however, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumors immunotherapy was not shown in this study and must be evaluated in subsequent trials.
Self-amplifying RNA vaccines for infectious diseases
TLDR
How self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages of synthetic manufacturing approaches, and their potential for preventing and treating chronic infections are explored.
DNA Vaccines—How Far From Clinical Use?
TLDR
Improvements in DNA vaccine design include the use of APC-specific promotors for transcriptional targeting, the arrangement of multiple antigen sequences, the co-delivery of molecular adjuvants to prevent tolerance induction, and strategies to circumvent potential inhibitory effects of the vector backbone.
Self-amplifying mRNA vaccines.
...
...